Editorial: Diabetes and cardiovascular disease: new therapeutic interventions.
作者信息
Trotta Maria Consiglia, D'Amico Michele, Weckbach Ludwig T, Hermenean Anca, Ferraro Bartolo
机构信息
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
出版信息
Front Pharmacol. 2024 Aug 12;15:1472636. doi: 10.3389/fphar.2024.1472636. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Diabetes and cardiovascular disease: new therapeutic interventions.社论：糖尿病与心血管疾病：新的治疗干预措施
Front Pharmacol. 2024 Aug 12;15:1472636. doi: 10.3389/fphar.2024.1472636. eCollection 2024.
2
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus.2 型糖尿病患者的危险因素控制与心血管事件。
PLoS One. 2024 Feb 29;19(2):e0299035. doi: 10.1371/journal.pone.0299035. eCollection 2024.
3
Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings.在一级和二级预防环境中，2 型糖尿病患者的危险因素控制与心血管事件风险。
Circulation. 2020 Nov 17;142(20):1925-1936. doi: 10.1161/CIRCULATIONAHA.120.046783. Epub 2020 Nov 16.
4
Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.胰高血糖素样肽-1受体激动剂在糖尿病心肾疾病中的作用：临床及临床前证据的最新进展
Curr Diabetes Rev. 2024;20(6):e090823219597. doi: 10.2174/1573399820666230809152148.
5
Editorial: Debates in cardiovascular pharmacology and drug discovery: 2022.社论：心血管药理学与药物研发辩论：2022年
Front Cardiovasc Med. 2023 Oct 18;10:1304680. doi: 10.3389/fcvm.2023.1304680. eCollection 2023.
6
Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications.特殊促消退脂质介质：对糖尿病相关心脏、肾脏和视网膜血管并发症的调节作用
Front Pharmacol. 2018 Dec 19;9:1488. doi: 10.3389/fphar.2018.01488. eCollection 2018.
7
Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.精准心脏肿瘤学建模：利用人诱导多能干细胞进行风险分层和预防。
Curr Oncol Rep. 2021 May 3;23(7):77. doi: 10.1007/s11912-021-01066-2.
8
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.N-末端脑利钠肽前体（NT-proBNP）可预测高肾心血管风险的 2 型糖尿病患者对阿利克仑的心脏肾脏反应。
Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.
9
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.利用多种风险标志物的短期变化预测阿利吉仑在ALTITUDE研究中对肾脏和心血管的疗效。
Eur J Prev Cardiol. 2014 Apr;21(4):434-41. doi: 10.1177/2047487313481754. Epub 2013 Mar 6.
10
The Haptoglobin genotype predicts cardio-renal mortality in type 1 diabetes.触珠蛋白基因型可预测1型糖尿病患者的心肾死亡率。
J Diabetes Complications. 2016 Mar;30(2):221-6. doi: 10.1016/j.jdiacomp.2015.11.011. Epub 2015 Nov 14.
本文引用的文献
1
Prevalence and risk of diabetic complications in young-onset versus late-onset type 2 diabetes mellitus.早发性与晚发性 2 型糖尿病患者的糖尿病并发症患病率和风险。
Diabetes Metab. 2022 Nov;48(6):101389. doi: 10.1016/j.diabet.2022.101389. Epub 2022 Sep 19.
2
Overview of key molecular and pharmacological targets for diabetes and associated diseases.糖尿病及相关疾病的关键分子和药理学靶点概述。
Life Sci. 2021 Aug 1;278:119632. doi: 10.1016/j.lfs.2021.119632. Epub 2021 May 18.
3
Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.糖尿病中的心血管风险：疾病并发症还是降糖药物所致？
Clin Pharmacol Ther. 2015 Aug;98(2):145-61. doi: 10.1002/cpt.143. Epub 2015 Jul 3.
Zotero 插件